Clinical Trials Browser

Phase 1 × Withdrawn × Capecitabine × Clear all

Clinical Stage I Gastric Cancer AJCC v8

NCT02831179 2017-09-28

Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor

DermatologicEndocrineGastrointestinalNET

Non functioning pancreatic endocrine tumor, Adrenal Cortex Neoplasms, Carcinoid Tumor, Vipoma, Glucagonoma, Insulinoma, Pheochromocytoma, Somatostatinoma, Zollinger-Ellison Syndrome, Carcinoma, Merkel Cell, Carcinoma, Medullary, Neuroendocrine Tumors, Multiple Endocrine Neoplasia Type 1, Multiple Endocrine Neoplasia Type 2a, Multiple Endocrine Neoplasia Type 2b

NCT02915172 2017-06-26

Lenvatinib and Capecitabine in Patients With Advanced Malignancies

Phase 1 Withdrawn

BreastGenitourinary

Breast Neoplasms, Urologic Neoplasms

NCT03117855 2017-04-18

Capecitabine and Y-90 Radioembolization in Treating Patients With Advanced Bile Duct Cancer in the Liver That Cannot Be Removed by Surgery

Phase 1 Withdrawn

Gastrointestinal

Cholangiocarcinoma

NCT00118300 2011-07-08

Capecitabine and Radiation Therapy in Treating Patients With Locally Advanced Cervical Cancer or Other Pelvic Cancer

Phase 1 Withdrawn

Gynecologic

Carcinoma, Ovarian Epithelial, Uterine Cervical Neoplasms, Ovarian Neoplasms, Vaginal Neoplasms, Endometrial Neoplasms

Clinical Trials

Neoadjuvant Therapy for the Treatment of Gastroesophageal Junction and Gastric Cancers

Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor

Lenvatinib and Capecitabine in Patients With Advanced Malignancies

Capecitabine and Y-90 Radioembolization in Treating Patients With Advanced Bile Duct Cancer in the Liver That Cannot Be Removed by Surgery

Capecitabine and Radiation Therapy in Treating Patients With Locally Advanced Cervical Cancer or Other Pelvic Cancer